Effects of enalapril and folic acid tablets on hypertension patients with hyperhomocysteinemia and paroxysmal atrial fibrillation

LIU Yujie; XU Wu

doi:10.3969/j.issn.2096-3882.2021.07.012

Journal of Xuzhou Medical University > 2021 > 41(7): 534-539. > DOI: 10.3969/j.issn.2096-3882.2021.07.012

LIU Yujie, XU Wu. Effects of enalapril and folic acid tablets on hypertension patients with hyperhomocysteinemia and paroxysmal atrial fibrillation[J]. Journal of Xuzhou Medical University, 2021, 41(7): 534-539. DOI: 10.3969/j.issn.2096-3882.2021.07.012

Citation:

PDF (2507 KB)

Effects of enalapril and folic acid tablets on hypertension patients with hyperhomocysteinemia and paroxysmal atrial fibrillation

LIU Yujie^1,2,
XU Wu^3, ,

1. The First Clinical Medical College, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China;
2. Fengxian People's Hospital, Fengxian, Jiangsu 221700;
3. Department of Cardiology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002

More Information

Received Date: September 19, 2020
Revised Date: June 27, 2021

Graphical Abstract

Abstract

Abstract

Objective To observe the clinical effects of enalapril and folic acid tablets on hypertension patients with high homocysteine (Hcy) level and paroxysmal atrial fibrillation, so as to provide evidence for diagnosis and treatment. Methods A total of 108 hypertension patients with high Hcy level and paroxysmal atrial fibrillation were randomly divided into three groups (n=36), and treated with amlodipine, enalapril or enalapril folic acid tablets for 12 months. Their blood pressure, Hcy, left atrial diameter (LAD), left atrial function index (LAFI), left atrial volume index (LAVI), diastolic global diastolic strain (Sg), systolic strain rate (SRs), standard deviations of time to peak global diastolic strain rate (TPSRg-SD), and standard deviations of time to peak global diastolic strain rate (TPSRg-SD) before and after treatment were detected. Results There were 106 out of 108 patients who finished the study. After treatment with amlodipine, enalapril or enalapril and folic acid, the occurrence of atrial fibrillation significantly decreased in the three groups, which were statistically different (P<0.01). The enalapril and folic acid group showed better protective effects than the other two groups. Compared with the amlodipine group, the levels of LAD and NT-proBNP in the enalapril group and the enalapril and folic acid group significantly decreased (P<0.01). Furthermore, compared with those in the enalapril group and the amlodipine group, remarkable decreases were found in Hcy, LAVI, TPSRg-SD, and TPSRs-SD in the enalapril and folic acid group, but increases were seen in LAFI, Sg, and SRs in the enalapril group and the amlodipine group (P<0.05). There were no reports concerning cardiac dysfunction, stroke or death in each group. Conclusions Enalapril and folic acid tablets can reduce the occurrence of atrial fibrillation in hypertension patients with hyperhomocysteinemia and paroxysmal atrial fibrillation, which may be associated with the mechanism of inhibiting atrial remodeling.
- enalapril folate,
- paroxysmal atrial fibrillation,
- hypertension,
- Hcy

FullText(HTML)

References (19)

References

[1]	王小斌,夏振伟,冯磊.同型半胱氨酸水平和阵发性房颤患者射频消融术后复发的关系[J].解放军预防医学杂志,2019,37(4):43-44.
[2]	Yao Y,Yao W,Bai R,et al.Plasma homocysteine levels predict early recurrence after catheter ablation of persistent atrial fibrillation[J].Europace,2017,19(1):66-71.
[3]	Nasso G,Bonifazi R,Romano V,et al.Increased plasma homocysteine predicts arrhythmia recurrence after minimally invasive epicardial ablation for nonvalvular atrial fibrillation[J].J Thorac Cardiovasc Surg,2013,146(4):848-853.
[4]	Naji F,Suran D,Kanic V,et al.High homocysteine levels predict the recurrence of atrial fibrillation after successful electrical cardioversion[J].Int Heart J,2010,51(1):30-33.
[5]	Snezhitsky VA,Yatskevich ES,Doroshenko EM,et al.Homocysteine as a prognostic marker of atrial remodeling and clinical picture in patients with paroxysmal and persistent forms of atrialfibrillation[J].Klin Med (Mosk),2016,94(1):16-22.
[6]	de Vos CB,Pisters R,Nieuwlaat R,et al.Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis [J].J Am Coll Cardiol,2010,55(8):725-731.
[7]	Stanhewicz AE,Kenney WL.Role of folic acid in nitric oxide bioavailability and vascular endothelial function[J].Nutr Rev,2017,75(1):61-70.
[8]	中华人民共和国卫生部药政局.新药西药临床研究指导原则汇编[S].中华人民共和国卫生部药政局,1993.
[9]	Kirchhof P,Benussi S,Kotecha D,et al.ESC Scientific Document Group (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J].Eur Heart,2016,37(1):2893-2962.
[10]	Pappone C,Radinovic A,Manguso F,et al.Atrial fibrillation progression and management:A 5-year prospective follow-up study[J].Heart Rhythm,2008,5(11):1501-1507.
[11]	Im SI,Chun KJ,Park SJ,et al.Long-term prognosis of paroxysmal atrial fibrillation and predictors for progression to persistnt or chronic atrial fibrillation in the Korean population[J].J Korean Med Sci,2015,30(7):895-902.
[12]	Zoni-Berisso M,Lercari F,Carazza T,et al.Epidemiology of atrial fibrillation:European perspective[J].Clin Epidemiol,2014,6:213-220.
[13]	Calkins H,Hindricks G,Cappato R,et al.2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation[J/OL].Heart Rhythm,2017,14(10):e275-e444.
[14]	Matsushima S,Tsutsui H,Sadoshima J.Physiological and pathological functions of NADPH oxidases during myocardial ischemia-reperfusion[J].Trends Cardiovasc Med,2014,24(5):202-205.
[15]	Ramaraj R.Role of the renin-angiotensin system in the promotion of atrial fibrillation[J].Acta Cardiol,2009,64(6):843.
[16]	Jibrini MB,Molnar J,Arora RR.Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system:a systematic review and meta-analysis[J].Am J Ther,2008,15(1):36-43.
[17]	Schneider M, Hua TA,Bohm M,et al.Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis.[J].J Am Coll Cardiol,2010,55(21):299-307.
[18]	Tao LX,Yang K,Wu J,et al.Association between plasma homocysteine and hypertension:Results from a cross-sectional and longitudinal analysis in Beijing's adult population from 2012 to 2017[J].J Clin Hypertens (Greenwich),2018,20(11):1624-1632.
[19]	Steed MM,Tyagi SC.Mechanisms of cardiovascular remodeling in hyperhomocysteinemia[J].Antioxid Redox Signal,2011,15(7):1927-1943.

Cited By

Get Citation

PDF

XML

Article views (660) PDF downloads (706)

Turn off MathJax

Article Contents

Abstract

References

Effects of enalapril and folic acid tablets on hypertension patients with hyperhomocysteinemia and paroxysmal atrial fibrillation

Abstract

References

Catalog

Export File

Citation

Format

Content